Best Medical International, Inc. v. Varian Medical Systems, Inc.

CourtDistrict Court, D. Delaware
DecidedJuly 21, 2020
Docket1:18-cv-01599
StatusUnknown

This text of Best Medical International, Inc. v. Varian Medical Systems, Inc. (Best Medical International, Inc. v. Varian Medical Systems, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Best Medical International, Inc. v. Varian Medical Systems, Inc., (D. Del. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE BEST MEDICAL INTERNATIONAL, ) INC., ) ) Plaintiff, ) ) v. ) C.A. No. 18-1599 (MN) ) VARIAN MEDICAL SYSTEMS, INC. and ) VARIAN MEDICAL SYSTEMS ) INTERNATIONAL AG, ) ) Defendants. )

MEMORANDUM ORDER

At Wilmington this 21st day of July 2020: IT IS HEREBY ORDERED that the claim terms of U.S. Patent Nos. 6,038,283 (“the ’283 Patent”) and 6,393,096 (“the ’096 Patent”) with agreed-upon constructions are construed as follows (see D.I. 120, Exhibit A at A-1): 1. “approach correspondence of” means “improve agreement of” (’283 Patent, cl. 6-7; ’096 Patent, cl. 18); 2. “correspondence to” means “agreement with” (’283 Patent, cl. 46); 3. “conform to” means “improve agreement with” (’096 Patent, cl. 31, 33); 4. “cost zone” means “region relative to a CDVH curve” (’096 Patent, cl. 21, 23); and 5. “zone” means “region relative to a CDVH curve” (’283 Patent, cl. 7, 12; ’096 Patent, cl. 21, 23). Further, as announced at the hearing on June 26, 2020, IT IS HEREBY ORDERED that the disputed claim terms of the ’283 Patent, the ’096 Patent, and U.S. Patent Nos. 7,266,175 (“the ’175 Patent”) and 7,015,490 (“the ’490 Patent”) are construed as follows: 1. “computer . . . to computationally”: (A) “obtain a proposed beam arrangement” (’283 Patent, cl. 6-7, 12, 24-25, 27-28; ’096 Patent, cl. 18, 31, 33), (B) “obtain a set of proposed beam weights” (’283 Patent, cl. 46), (C) “change the proposed radiation beam arrangement iteratively” (’283 Patent, cl. 6-7, 12, 24-25, 27-28; ’096 Patent, cl. 18, 31, 33), (D) “change the set of proposed beam weights iteratively” (’283 Patent, cl. 46), and (E) “calculate [an/the] optimized radiation beam arrangement” (’283 Patent, cl. 42, 46; ’096 Patent, cl. 44, 46), has its plain and ordinary meaning in each instance; 2. “objective cost function” means “mathematical function that determines a cost value based upon objective factors” (’175 Patent, cl. 13, 15, 19); 3. “optimizer” means “program or device that iteratively attempts to find a preferred solution” (’175 Patent, cl. 13, 15, 19); 4. “intensity map[s]” means “a representation of the variation across a defined area of radiation of a single beam” (’175 Patent, cl. 13, 15, 19); 5. “determine [a/the] collimator angle of [a/the] multi-leaf collimator” means “select [a/the] rotation angle of [a/the] multi-leaf collimator” (’490 Patent, cl. 4, 17-18).1 The parties briefed the issues (see D.I. 85), submitted an appendix containing both intrinsic and extrinsic evidence, including expert declarations2 (D.I. 86, 87, 88), and a supplemental

1 During the hearing, the parties reached agreement as to the construction of this term. In coming to that agreement, both sides agreed that a gantry angle is different from a collimator angle and that changing the gantry angle is not the same as changing the collimator angle. See infra.

2 Defendants Varian Medical Systems, Inc. and Varian Medical Systems International AG (collectively, “Defendants” or “Varian”) submitted declarations from Timothy D. Solberg, Ph.D., a Professor of Radiation Oncology and Vice Chair of the Division of Medical Physics at the University of California, San Francisco, and Kenneth P. Gall, Ph.D., an independent consultant in the field of medical devices, specifically radiation therapy, with their answering brief. (See D.I. 88, Ex. 29-30). Plaintiff Best Medical International, Inc. (“Plaintiff” or “Best”) submitted the declaration of Chester R. Ramsey, Ph.D., Director of Medical Physics for the Thompson Cancer Survival Center, with its reply. (See id., Ex. appendix (D.I. 121). Each side also provided a tutorial describing the relevant technology. (See D.I. 115 & 116). The Court carefully reviewed all submissions in connection with the parties’ contentions regarding the disputed claim terms, heard oral argument (see D.I. 132), and applied the following legal standards in reaching its decision.

I. LEGAL STANDARD “[T]he ultimate question of the proper construction of the patent [is] a question of law,” although subsidiary fact-finding is sometimes necessary. Teva Pharms. USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831, 837-38 (2015). “[T]he words of a claim are generally given their ordinary and customary meaning [which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc) (internal citations and quotation marks omitted). Although “the claims themselves provide substantial guidance as to the meaning of particular claim terms,” the context of the surrounding words of the claim also must be considered. Id. at 1314. “[T]he ordinary meaning of a claim term is its meaning

to the ordinary artisan after reading the entire patent.” Id. at 1321 (internal quotation marks omitted). The patent specification “is always highly relevant to the claim construction analysis . . . [as] it is the single best guide to the meaning of a disputed term.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996). It is also possible that “the specification may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess. In such cases, the inventor’s lexicography governs.” Phillips, 415 F.3d at

44-46). Additional declarations were also included in the IPR filings submitted. (See, e.g., id., Ex. 21). 1316. “Even when the specification describes only a single embodiment, [however,] the claims of the patent will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words or expressions of manifest exclusion or restriction.” Hill-Rom Servs., Inc. v. Stryker Corp., 755 F.3d 1367, 1372 (Fed. Cir. 2014) (internal quotation marks

omitted) (quoting Liebel-Flarsheim Co. v. Medrad, Inc., 358 F.3d 898, 906 (Fed. Cir. 2004)). In addition to the specification, a court “should also consider the patent’s prosecution history, if it is in evidence.” Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed. Cir. 1995) (en banc), aff’d, 517 U.S. 370 (1996). The prosecution history, which is “intrinsic evidence, . . . consists of the complete record of the proceedings before the PTO [(Patent and Trademark Office)] and includes the prior art cited during the examination of the patent.” Phillips, 415 F.3d at 1317. “[T]he prosecution history can often inform the meaning of the claim language by demonstrating how the inventor understood the invention and whether the inventor limited the invention in the course of prosecution, making the claim scope narrower than it would otherwise be.” Id.

In some cases, courts “will need to look beyond the patent’s intrinsic evidence and to consult extrinsic evidence in order to understand, for example, the background science or the meaning of a term in the relevant art during the relevant time period.” Teva, 135 S. Ct. at 841.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Best Medical International, Inc. v. Varian Medical Systems, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/best-medical-international-inc-v-varian-medical-systems-inc-ded-2020.